/MIRA
MIRA Stock - MIRA Pharmaceuticals, Inc.
Healthcare|Drug Manufacturers - GeneralNASDAQ
$1.63+1.24%
+$0.02 (+1.24%) • Dec 19
67
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.94
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.47
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.79
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MIRA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.61 – $1.65
TARGET (TP)$1.87
STOP LOSS$1.50
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.81
52W High$2.45
52W Low$0.73
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-8,018,328 | $-8,526,049 | $-7,047,940 | $-2,152,162 | $-67,629 |
| Net Income | $-7,852,659 | $-11,982,343 | $-7,058,190 | $-2,176,536 | $-67,993 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.51 | $-0.65 | $-0.48 | $-0.15 | $-0.00 |
Company Overview
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MIRABeat Rate
44%
Last 9 quarters
Avg Surprise
-23.3%
EPS vs Estimate
Beats / Misses
4/4
1 met exactly
Latest EPS
$-1.18
Q4 2025
EPS Surprise History
Q2 24
-70.2%
$-0.39vs$-0.23
Q2 24
-20.0%
$-0.12vs$-0.10
Q3 24
-10.0%
$-0.11vs$-0.10
Q4 24
+22.2%
$-0.14vs$-0.18
Q1 25
+48.3%
$-0.15vs$-0.29
Q2 25
+26.7%
$-0.11vs$-0.15
Q3 25
+18.2%
$-0.09vs$-0.11
Q4 25
0.0%
$-1.18vs$-1.18
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | $-1.18 | $-1.18 | 0.0% | = MET |
Q3 2025 | Aug 14, 2025 | $-0.11 | $-0.09 | +18.2% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q1 2025 | Mar 28, 2025 | $-0.29 | $-0.15 | +48.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.10 | $-0.11 | -10.0% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.10 | $-0.12 | -20.0% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.23 | $-0.39 | -70.2% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.08 | $-0.26 | -225.0% | ✗ MISS |
Q3 2023 | Sep 15, 2023 | — | $-0.10 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.09 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-43.86 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.12 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.16 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.10 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.00 | — | — |
Latest News
Mira Pharmaceuticals Q3 EPS $(1.18) Misses $(0.08) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 01:50 PM
MIRA Pharma Initiates Multiple Ascending Dose Portion Of Ongoing Phase 1 Clinical Trial Evaluating Lead Oral Candidate, Ketamir-2, In Healthy Volunteers
📈 PositiveBenzinga•Oct 24, 2025, 11:31 AM
MIRA Pharmaceuticals Initiates The Multiple Ascending Dose Portion Of Its Ongoing Phase 1 Clinical Trial, Evaluating Its Lead Oral Candidate, Ketamir-2, In Healthy Volunteers; Advancing Toward Phase 2a Clinical Evaluation In Chemotherapy-Related Pain, A Condition With No Approved Treatments And Potential For FDA Fast Track Consideration
📈 PositiveBenzinga•Oct 23, 2025, 08:48 PM
MIRA Pharmaceuticals Sells 1,751,000 Shares At $2.19 Each
➖ NeutralBenzinga•Oct 16, 2025, 08:21 PM
MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data for Mira-55.
📈 PositiveBenzinga•Oct 16, 2025, 12:50 PM
Market-Moving News for October 16th
➖ NeutralBenzinga•Oct 16, 2025, 11:14 AM•Also: ,
MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data for Mira-55.
📈 PositiveBenzinga•Oct 15, 2025, 08:25 PM
Mira Pharmaceuticals Reports New Preclinical Data Showing That Oral Administration Of Mira-55 Normalized Pain And Significantly Reduced Inflammation, Outperforming Injected Morphine In A Chronic Inflammatory Pain Model
📈 PositiveBenzinga•Oct 15, 2025, 08:06 PM
MIRA Pharmaceuticals Says Phase 1 SAD Study Demonstrated That Ketamir-2 Was Safe And Well Tolerated At All Dose Levels
📈 PositiveBenzinga•Sep 22, 2025, 11:36 AM
MIRA Pharmaceuticals Reports Ketamir-2 Restored Normal Behavior In PTSD Animal Study, Expands Focus Beyond Pain
📈 PositiveBenzinga•Sep 16, 2025, 11:37 AM
MIRA stock has given up its prior gain. MIRA Pharmaceuticals shares were trading higher after the company announced results from a proof-of-concept validation study evaluating Ketamir-2 in an animal model of post-traumatic stress disorder
➖ NeutralBenzinga•Sep 15, 2025, 09:31 PM
MIRA Pharmaceuticals shares are trading higher after the company announced results from a proof-of-concept validation study evaluating Ketamir-2 in an animal model of post-traumatic stress disorder
📈 PositiveBenzinga•Sep 15, 2025, 08:16 PM
MIRA Pharmaceuticals Announces Ketamir-2 Reverses PTSD-Like Symptoms In Animal Study, Supporting Ongoing Clinical Development
📈 PositiveBenzinga•Sep 15, 2025, 08:14 PM
Mira Pharmaceuticals Announces PTSD Data For Ketamir-2
➖ NeutralBenzinga•Sep 15, 2025, 08:05 PM
MIRA Pharmaceutical shares are trading lower after the company announced that it approved the acquisition of SKNY Pharmaceuticals
📉 NegativeBenzinga•Sep 12, 2025, 03:43 PM
MIRA Pharmaceuticals Shareholders Approve Acquisition Of SKNY Pharma; Adds SKNY-1 Oral Candidate Showing 30% Weight Loss & Nicotine Craving Reversal; Deal Valued At $60M Combined Entity
📈 PositiveBenzinga•Sep 12, 2025, 11:32 AM
MIRA Pharmaceuticals Completes Phase 1 Single Ascending Dose Portion Of Phase 1 Trial Of Ketamir-2
📈 PositiveBenzinga•Aug 19, 2025, 12:42 PM
Frequently Asked Questions about MIRA
What is MIRA's current stock price?
MIRA Pharmaceuticals, Inc. (MIRA) is currently trading at $1.63 per share. The stock has moved +1.24% today.
What is the analyst price target for MIRA?
No analyst price targets are currently available for this stock.
What sector is MIRA Pharmaceuticals, Inc. in?
MIRA Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NASDAQ exchange.
What is MIRA's market cap?
MIRA Pharmaceuticals, Inc. has a market capitalization of $0.07 billion, making it a small-cap company.
Does MIRA pay dividends?
No, MIRA Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
APUS
Apimeds Pharmaceuticals US, Inc
$1.52
Mkt Cap: $0.0B
IGC
IGC Pharma, Inc.
$0.30
Mkt Cap: $0.0B
MLSS
Milestone Scientific Inc.
$0.32
Mkt Cap: $0.0B
MODD
Modular Medical, Inc.
$0.34
Mkt Cap: $0.0B
MYO
Myomo, Inc.
$0.93
Mkt Cap: $0.0B
NNVC
NanoViricides, Inc.
$1.24
Mkt Cap: $0.0B
POCI
Precision Optics Corporation, Inc.
$4.08
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
TLPH
Talphera, Inc.
$1.10
Mkt Cap: $0.0B
Explore stocks similar to MIRA for comparison